Sign Up
Sign In
My Hubs
You have not joined any Hubs. Please Browse to join hubs

ImClone plays hard to get, considers spin-off

FierceBiotech |  August 5th, 2008 | Email this
Don't expect Carl Icahn to be grabbing any first bid that comes his way--especially if it's Bristol-Myers Squibb's paltry $4.5 billion for ImClone, where the renegade investor now holds sway as chairman of the board. The company is studying the offer, but says the bid "substantially undervalues" its worth. And [...]

(Optional)

(Optional)

*(Separate multiple emails with commas.)


(Optional)
  
If you are not a bot, Please don't fill the "Robot Fill" field
Robot Fill
 
Related Organizations
 
-->